Eli Lilly and UnitedHealth to study Lilly’s antibody treatment bamlanivimab in high-risk COVID patients

/ / News

Eli Lilly & Co. and UnitedHealth Group Inc. said Friday they are joining forces for a study of Lilly’s bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. Food and Drug Administration emergency use authorization as a treatment for mild to moderate COVID-19 patients, who are at high risk of getting a severe case of the virus and/or requiring hospitalization. “The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations ,” the companies said in a joint statement. “Larger pragmatic studies in diverse populations can help us further understand the efficacy and safety of SARS-CoV-2 neutralizing antibodies in real world settings,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. Eli Lilly shares were not active premarket, while UnitedHealth was slightly higher.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.